Par Drugs And Chemicals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Going-concern doubtResults View source PDF Explain this filing

PAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.9%Reaction day

₹92.70

prior close

₹90.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.4%-5.6% vs market

Pharmaceuticals peers, median of 160sector-0.1%-5.8% vs sector

On the reaction day the stock moved 5.6 pts less than Nifty Microcap 250 and 5.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-1.6

15m

-1.7

30m

-2.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.9-0.4-5.6-0.1-5.8

Next day

-9.4-1.7-7.7-0.9-8.5

-7.9-1.3-6.6-0.2-7.7

-8.3-0.7-7.6+0.3-8.6

-9.5+0.4-9.9+1.1-10.6

-6.8+0.5-7.3+0.2-7.0

-0.8+2.8-3.6+1.0-1.7

15d

-8.3+1.2-9.5-0.2-8.1

+0.6+5.3-4.7+1.7-1.1

+11.1+9.9+1.2+7.7+3.4

+7.6+13.1-5.6+8.1-0.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Par Drugs and Chemicals Limited's Board approved its audited financial results for Q4 and FY2025-26 ended March 31, 2026. The statutory auditor issued an UNMODIFIED (clean) opinion on the standalone financial results. However, the Auditor's Report identified a Key Audit Matter regarding the company's ability to continue as a going concern due to SEBI's Ex-Parte Interim Order and Confirmatory Order restraining the proposed Business Transfer Arrangement (BTA) involving slump sale of the primary business to a related party. The company is evaluating legal remedies to challenge these orders. No outstanding defaults on loans or debt securities were reported. The board also renewed banking facilities of Rs. 161 lakh with Kotak Mahindra Bank and authorized investments up to Rs. 90 crore in liquid/arbitrage funds and fixed deposits.

Likely market impact

While the auditor issued a clean opinion, the SEBI regulatory order blocking the business transfer remains a significant uncertainty that could impact the company's future operations and strategy. Shareholders should monitor the outcome of the company's legal challenge to SEBI's orders.